Nilotinib after imatinib first‐line: a real‐life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|180|3|356-364

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.180, Iss.3, 2018-02, pp. : 356-364

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy

By  

Acta Haematologica, Vol. 118, Iss. 3, 2007-09 ,pp. : 162-164

Karger

Access to resources Recommend Favorite

Treatment‐free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 2, 2015-01 ,pp. : 305-308

John Wiley & Sons Inc

Access to resources Recommend Favorite

Resolution of Roth spots in chronic myeloid leukaemia after treatment with imatinib

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 6, 2015-09 ,pp. : 744-744

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term results of high‐dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 3, 2015-08 ,pp. : 398-407

John Wiley & Sons Inc

Access to resources Recommend Favorite

More about Imatinib and Nilotinib Combination Therapy in Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-09 ,pp. : 18-19

Karger

Access to resources Recommend Favorite